{"type":"trials","record":{"id":42204,"source_id":"clinicaltrials-gov","external_id":"NCT02157077","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","brief_summary":"The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Centre Hospitalier Intercommunal Creteil","enrollment":90,"countries":["France"],"start_date":"2013-12-01","completion_date":"2015-12-01","last_update_date":"2022-12-06","source_url":"https://clinicaltrials.gov/study/NCT02157077","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ARI2","age_range":"50 Years","comparator":null,"organization":"Centre Hospitalier Intercommunal Creteil","interventions":["Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks — Baseline and 12 weeks","Change from baseline in central retinal thickness by SD OCT at 12 weeks — Baseline and 12 weeks","Change from Baseline in visual acuity at 12 weeks — Baseline and 12 weeks","Change from Baseline in volume of pigment epithelium detachment at 12 weeks — Baseline and 12 weeks","Association with genes involved in AMD history — genetic testing will be performed when all the particpitants will be r…","Number of participants with adverse events from baseline to 32 weeks — from baseline to 32 weeks","Change from Baseline in pigment epithelium detachment height at 12 weeks — Baseline and 12 weeks","Change from baseline in central retinal thickness at 32 weeks — baseline and 32 weeks","Change from Baseline in pigment epithelium detachment height at 32 weeks — Baseline and 32 weeks","Change from Baseline in visual acuity at 32 weeks — Baseline and 32 weeks","Change from Baseline in volume of pigment epithelium detachment at 32 weeks — Baseline and 32 weeks"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Macular Degeneration","Wet Macular Degeneration","Retinal Degeneration","Retinal Diseases","Eye Diseases","Aflibercept"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02157077","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2013-12-01 to 2015-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.935Z","intervention":["Aflibercept"],"participants":90,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks — Baseline and 12 weeks","Change from baseline in central retinal thickness by SD OCT at 12 weeks — Baseline and 12 weeks","Change from Baseline in visual acuity at 12 weeks — Baseline and 12 weeks","Change from Baseline in volume of pigment epithelium detachment at 12 weeks — Baseline and 12 weeks","Association with genes involved in AMD history — genetic testing will be performed when all the particpitants will be r…","Number of participants with adverse events from baseline to 32 weeks — from baseline to 32 weeks","Change from Baseline in pigment epithelium detachment height at 12 weeks — Baseline and 12 weeks","Change from baseline in central retinal thickness at 32 weeks — baseline and 32 weeks","Change from Baseline in pigment epithelium detachment height at 32 weeks — Baseline and 32 weeks","Change from Baseline in visual acuity at 32 weeks — Baseline and 32 weeks","Change from Baseline in volume of pigment epithelium detachment at 32 weeks — Baseline and 32 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42204","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}